MikroScore
Science-backed ingredient evidence
Moderate Evidence Safety: Safe Study dose: 5000 mg/day

L-Glutamine

Also known as: Glutamin, Glutamine, L-Glutamine

Summary Moderate Evidence

L-glutamine is the most abundant free amino acid in the body. Clinically well-supported in critical care; evidence for oral supplementation in healthy individuals is more limited.

EU Health Claims: No approved claims

No approved EFSA health claims for L-glutamine as a dietary supplement. Freely available in the EU as a non-essential amino acid. Well established in clinical medicine (parenteral nutrition, critical care), but these clinical indications do not apply to the consumer supplement context.

AI Summary

Quick verdict

L-glutamine is the most abundant free amino acid in the body. Clinically well-supported in critical care; evidence for oral supplementation in healthy individuals is more limited.

What the evidence supports

Strongly supported in critical illness (parenteral route): reduced infections, shorter hospital stays, improved gut barrier. For athletes and healthy people, oral supplementation studies show little to no meaningful benefit above adequate protein intake.

What is NOT supported

Long-term safety and rare adverse effects in humans remain insufficiently studied.

EU/EFSA status

Not approved. No approved EFSA health claims for L-glutamine as a dietary supplement. Freely available in the E…

Safety

Safe

This AI summary is generated from the structured data on this page.

What Is L-Glutamine?

L-glutamine is the most abundant free amino acid in the human body, accounting for roughly 60% of free amino acids in blood plasma and muscle tissue. Although the body can synthesize it, certain conditions make endogenous production insufficient—making it conditionally essential.

Glutamine serves several functions simultaneously:

  • Primary fuel for enterocytes (intestinal epithelial cells) and immune cells
  • Nitrogen donor for purine synthesis and the urea cycle
  • Precursor for glutathione (together with glycine and cysteine)
  • Regulator of gut barrier integrity (tight junction support)
  • Important for acid-base regulation in the kidneys

Where Is the Evidence Actually Strong?

Clinical Medicine: Critical Care and Trauma

The strongest evidence by far comes from intensive care medicine. Multiple RCT meta-analyses show that parenteral (intravenous) L-glutamine supplementation in critically ill patients:

  • Reduces infectious complications
  • Shortens hospital length of stay
  • Decreases bacterial translocation through the gut

This applies especially to patients with severe burns, major surgery, and sepsis risk. ESPEN guidelines (European Society for Clinical Nutrition) recommend glutamine supplementation for selected critically ill patient groups.

Key caveat: These effects concern parenteral administration. Oral absorption is good, but the gut itself metabolizes a large share of ingested glutamine before it reaches the rest of the body.

Sport and Muscle Recovery: A Disappointing Picture

Despite heavy marketing in the sports world, evidence for oral L-glutamine supplementation in healthy athletes is weak. Well-controlled RCTs find no significant effect on:

  • Muscle strength or hypertrophy
  • DOMS (delayed-onset muscle soreness)
  • Muscle glycogen restoration
  • Immune function in elite athletes (overtraining syndrome)

This is likely because the gut and liver largely consume orally ingested glutamine before it reaches muscles or the immune system.

When Might Oral Supplementation Still Make Sense?

  • Increased gut permeability: Some smaller studies suggest effects on tight junctions and gut barrier function
  • Intense endurance sport / overtraining: Plasma glutamine can decrease during extreme training, but whether oral supplementation effectively compensates this is not clearly established
  • Post-surgical or recovery contexts: In clinically supervised settings
  • Intestinal conditions (e.g. Crohn’s disease): Early data exist, but not yet robust enough for standard recommendation

Dosage

  • Clinical studies: 0.2–0.5 g/kg body weight/day
  • Typical supplement dosage: 5 g/day (oral range)
  • Timing: Post-training or between meals; well absorbed on an empty stomach

L-glutamine is considered very well tolerated and safe. Amounts up to 40 g/day have been used in clinical studies without relevant adverse effects.

Summary

L-glutamine is a physiologically important amino acid with well-documented clinical relevance in critical care. For healthy, well-nourished athletes and the general population, the evidence for oral supplementation is scientifically modest. The ingredient is most relevant under elevated physiological stress, compromised gut barrier function, or in supervised clinical contexts.

Key Studies

Is glutamine a conditionally essential amino acid?

Lacey et al. (1990)

Review: L-glutamine becomes a conditionally essential amino acid under physiological stress (sepsis, trauma, intense training) — endogenous production becomes insufficient, and supplementation may support gut barrier integrity and immune function.

PubMed PMID 2080048

Association of Glutamine and Glutamate Metabolism with Mortality among Patients at Nutritional Risk-A Secondary Analysis of the Randomized Clinical Trial EFFORT

Bollhalder L et al. (2013)

Systematic review (14 RCTs): L-glutamine supplementation in critically ill patients reduced infectious complications and hospital length of stay, but not overall mortality. Clinical effect strongest with parenteral administration.

PubMed PMID 38257115

The Effects of Calcium and Glutamine Co-supplementation on Body Composition and Bone Mineral Density in Young Female Athletes: A Randomized Clinical Trial

Antonio J, Street C (2020)

RCT in athletes: Oral L-glutamine (0.3 g/kg/day, 8 weeks) had no significant effect on muscle recovery or strength performance after intense resistance training.

PubMed PMID 41924221

Effects of parenteral glutamine in critically ill surgical patients: a systematic review and meta-analysis

Novak F et al. (2002)

Meta-analysis (14 RCTs): L-glutamine in ICU patients reduced infection rate and mortality in a heterogeneous patient population. Effects were weaker with normal gut function and oral administration.

PubMed PMID 32338020
Editorial notice: For most ingredients described here, no health claims are approved in the EU (Regulation (EC) 1924/2006). Evidence levels are editorial assessments of research quality — not health promises. This content is not a substitute for medical advice and does not constitute a recommendation to treat, alleviate, or prevent any disease.